Go to deals
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

UAB Nemuno vaistinė, operating under the brand name Camelia, is the leading pharmacy chain in Lithuania. The group carries out retail and wholesale trade in pharmaceuticals, food supplements, medical devices and cosmetics. Camelia’s pharmacy chain includes a countrywide network of approximately 300 own and 30 franchise outlets and manages one of the leading online pharmacies in Lithuania. Besides pharmacy retail and wholesale, the group is also involved in the development of pharmaceutical and nutraceutical products under its own brand names (private label).

Medigate Management UAB is a private investment holding company owned by Mr. Petras Bartkus (a minority shareholder in Camelia before the transaction). Medigate Management owns UAB Medigate, a developer and wholesaler of food supplements, medical devices and cosmetics in Lithuania.

CGP Management UAB is a private holding company owned by the founder of the Camelia pharmacy chain.

Oaklins’ team in Lithuania acted as the sole financial advisor to CGP Management on the sale of the Camelia pharmacy chain to Medigate Management.

Service
M&A sell-side
Parties

Talk to the deal team

 Mindaugas  Matulaitis

Mindaugas Matulaitis

Associate Partner

Vilnius, Lithuania
Oaklins Baltics
 Natalja  Titova

Natalja Titova

Associate Partner

Vilnius, Lithuania
Oaklins Baltics
 Agnė  Purlytė

Agnė Purlytė

Senior Analyst

Vilnius, Lithuania
Oaklins Baltics

Related deals

ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
Healthcare | TMT

ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners

Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.

Learn more
Poolbeg Pharma has completed an Initial Public Offering on AIM
Healthcare

Poolbeg Pharma has completed an Initial Public Offering on AIM

Poolbeg Pharma Plc has raised funds to develop the company.

Learn more
Kungshusen Medicinska has been acquired by Diploma
Healthcare

Kungshusen Medicinska has been acquired by Diploma

Kungshusen Medicinska AB has been acquired by Diploma PLC. Through the acquisition, Diploma gains access to a unique platform for the distribution of medtech products in Sweden.

Learn more